

## Sun Pharma inks agreement with Ferring Pharma for innovative obstetric drug

02 June 2021 | News

CARITEC® is indicated for the prevention of excessive bleeding in women after vaginal or caesarean child birth

A wholly-owned subsidiary of Sun Pharmaceutical Industries has entered into a license agreement with Ferring Pharmaceuticals (Ferring), a subsidiary of Switzerland-based biopharmaceuticals MNC Ferring Pharmaceuticals, to commercialise a Room Temperature Stable (RTS) formulation of the obstetric drug, CARITEC (Carbetocin RTS) in India. CARITEC is indicated for the prevention of excessive bleeding in women after vaginal or caesarean childbirth. The condition is commonly known as postpartum haemorrhage (PPH).

As per agreement terms, Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC. Ferring has developed the drug and received approval from the Drugs Controller General of India (DCGI) for introducing the drug in India.

Kirti Ganorkar, CEO-India business, Sun Pharma, said, "Through our collaboration with Ferring, we are introducing an innovative medicine that will help in reducing thousands of deaths from PPH every year. We believe this unique RTS formulation of Carbetocin will play an important role in PPH prevention in India."